Aarkstore - Sutent (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

1
Aarkstore - Sutent (Renal Cell
Carcinoma) - Analysis and Forecasts to
2022
Category Pharmaceuticals and Healthcare
2
Summary
Sutent (Renal Cell Carcinoma) - Analysis and
Forecasts to 2022 provides Sutent sales
forecasts for US, EU5 and Japan. In addition, it
covers detailed clinical assessment of the drug,
factors impacting drug sales, competitive
landscape, and analysis of sales performance
during the forecast period (2012-2022). The
report also includes information on Renal Cell
Carcinoma market. This report is built using data
and information sourced from Our proprietary
databases, primary and secondary research using
Companys corporate website, SEC filings,
investor presentations and featured press
releases, both from company and industry-specific
third party sources, put together with in-house
analysis, by Our team of industry experts.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/109483/sutent-renal-ce
ll-carcinoma-analysis-and-forecasts-to-2022
3
Scope

• Therapy area profile including patient population
  for the US, EU5 and Japan (seven major markets)
• Analysis and review of Sutent including sales
  data
• Qualitative and quantitative assessment of market
  space
• Analysis of the trends, drivers and restraints
  shaping and defining the markets
• In-depth analysis of Sutent including efficacy,
  safety, pricing, competition and other details
  which influence its sales potential
• - Detailed sales forecast for 2012-2022 for
  Sutent in the seven major markets

4
Reasons to buy

• - Understand and capitalize by identifying
  products that are most likely to ensure a robust
  return
• - Stay ahead of competition by understanding the
  changing competitive landscape
• - Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• - Make more informed business decisions from
  insightful and in-depth analysis of the drugs
  performance
• - Examine the historical sales performance of a
  drug in seven major markets
• - Obtain sales forecast for currently
  marketed/pipeline drug for 2012-2022 for all
  seven major markets

5
Table of Content

• 1.1 List of Tables
• 1.2 List of Figures
• 2 Introduction
• 2.1 RCC
• 2.1.1 Types of Renal Cell Carcinoma
• 2.2 RCC Market
• 2.3 Epidemiology
• 2.4 Pathophysiology
• 2.5 Etiology
• 2.5.1 Cigarette Smoking
• 2.5.2 Obesity

6
List of Tables

• Table 1 RCC, Incidences and Mortality, 2008-2030
• Table 2 RCC, TNM Classification
• Table 3 RCC, Fuhrman grading system
• Table 4 RCC, Treatment Guidelines
• Table 5 Sutent, Oncology, Global, Approval
  History
• Table 6 Sutent, Renal Cell Carcinoma, Drug Risk
  Benefit Score
• Table 7 Sutent, Renal Cell Carcinoma, Global,
  Annual Cost of Therapy, 2011
• Table 8 Sutent, RCC, Global Sales Forecasts
  (m), 20062014
• Table 9 Sutent, RCC, Global Sales Forecasts
  (m), 20152022
• Table 10 Sutent, RCC, The US, Sales Forecasts
  (m), 20062014
• Table 11 Sutent, RCC, The US, Sales Forecast
  (m), 20152022
• Table 12 Sutent, RCC, The UK, Sales Forecasts
  (m), 20062014
• Table 13 Sutent, RCC, The UK, Sales Forecasts
  (m), 20152022
• Table 14 Sutent, RCC, France, Sales Forecasts
  (m), 20062014
• Table 23 Sutent, RCC, Japan, Sales Forecasts
  (m), 20152022

7
List of Figures

• Figure 1 Worldwide Incidence and Mortality
  Distribution of Top 20 Cancers (), 2010
• Figure 2 Total number of cigarettes consumed,
  The US, 1976-2006
• Figure 3 RCC, Global, Market Size Forecasts
  (bn), 20102022
• Figure 4 RCC, Global, Incidence (in million),
  2008-2030
• Figure 5 Oncology, Worldwide, Incidence (in
  million), 2008-2030
• Figure 6 RCC, TNM Staging System
• Figure 7 RCC, Marketed drug targets
• Figure 8 RCC, Surgical Management
• Figure 9 Treatment Algorithm for Metastatic
  Renal Cell Carcinoma
• Figure 10 Classification of Patients with RCC
• Figure 11 Phase III results, Sutent Vs IFNa
• Figure 12 Drug Model Diagram of Sutent
• Figure 13 Sutent, RCC, Global Sales Forecasts
  (m), 20062022
• Figure 14 Sutent, RCC, The US, Sales Forecasts
  (m), 20062022

8
Related reports

• Lonsurf (Colorectal Cancer) - Forecast and Market
  Analysis to 2023
• Dupilumab (Atopic Dermatitis) - Forecast and
  Market Analysis to 2022
• Bococizumab (Acute Coronary Syndrome) - Forecast
  and Market Analysis to 2023
• PharmaPoint Dermatophytic Onychomycosis (DO) -
  US Drug Forecast and Market Analysis to 2022
• Dupilumab (Asthma) - Forecast and Market Analysis
  to 2023
• Dupilumab (Atopic Dermatitis) - Forecast and
  Market Analysis to 2022
• PharmaPoint Multiple Sclerosis - US Drug
  Forecast and Market Analysis to 2022
• PharmaPoint Migraine - US Drug Forecast and
  Market Analysis to 2023
• PharmaFocus Vaccine Adjuvants in Infectious
  Disease
• PharmaPoint Meningococcal Vaccines - Brazil Drug
  Forecast and Market Analysis to 2022

9

• Sutent (Renal Cell Carcinoma) - Analysis and
  Forecasts to 2022
• Published Mar 2012 51 Pages
• The report also includes information on Renal
  Cell Carcinoma market..
• Price

Formats Price
PDF 2000
Site License 4000
Enterprise Wide License 6000
10
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news